Landscapes / Companies
Alkermes, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
3
in active trials · 6 in all
Trials
9 active
21 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | Sep 2027Phase 3 trial completes | |||
| Next date | Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Bipolar I Disorder, Schizophrenia | ||||
| Open drug page | |||||
— |
Phase 3 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Narcolepsy Type 1, Narcolepsy Type 2 and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | Jul 2027Phase 2 trial completes | |||
| Next date | Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Attention Deficit Disorder With Hyperactivity (ADHD), Major Depressive Disorder (MDD) | ||||
| Open drug page | |||||
About
- No active trial
- ALKS 1140, ALKS 5461, Samidorphan
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021